Single Nucleotide Polymorphisms in CETP, SLC46A1, SLC19A1, CD36
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Variants of Lipid-Related Genes in Adult Japanese Patients with Severe Hypertriglyceridemia Akira Matsunaga1, Mariko Nagashima1, Hideko Yamagishi1 and Keijiro Saku2
The official journal of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Diseases Original Article J Atheroscler Thromb, 2020; 27: 1264-1277. http://doi.org/10.5551/jat.51540 Variants of Lipid-Related Genes in Adult Japanese Patients with Severe Hypertriglyceridemia Akira Matsunaga1, Mariko Nagashima1, Hideko Yamagishi1 and Keijiro Saku2 1Department of Laboratory Medicine, Fukuoka University School of Medicine, Fukuoka, Japan 2Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan Aim: Hypertriglyceridemia is a type of dyslipidemia that contributes to atherosclerosis and coronary heart dis- ease. Variants in lipoprotein lipase (LPL), apolipoprotein CII (APOC2), apolipoprotein AV (APOA5), glyco- sylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1), lipase maturation fac- tor 1 (LMF1), and glucokinase regulator (GCKR) are responsible for hypertriglyceridemia. We investigated the molecular basis of severe hypertriglyceridemia in adult patients referred to the Clinical Laboratory at Fukuoka University Hospital. Methods: Twenty-three adult patients with severe hypertriglyceridemia (>1,000 mg/dL, 11.29 mmol/L) were selected. The coding regions of candidate genes were sequenced by next-generation sequencing. Forty-nine genes reportedly associated with hypertriglyceridemia were analyzed. Results: In the 23 patients, we detected 70 variants: 28 rare and 42 common ones. Among the 28 rare variants with <1% allele frequency, p.I4533L in APOB, -
LRP2 Is Associated with Plasma Lipid Levels 311 Original Article
310 Journal of Atherosclerosis and Thrombosis Vol.14, No.6 LRP2 is Associated with Plasma Lipid Levels 311 Original Article Genetic Association of Low-Density Lipoprotein Receptor-Related Protein 2 (LRP2) with Plasma Lipid Levels Akiko Mii1, 2, Toshiaki Nakajima2, Yuko Fujita1, Yasuhiko Iino1, Kouhei Kamimura3, Hideaki Bujo4, Yasushi Saito5, Mitsuru Emi2, and Yasuo Katayama1 1Department of Internal Medicine, Divisions of Neurology, Nephrology, and Rheumatology, Nippon Medical School, Tokyo, Japan. 2Department of Molecular Biology-Institute of Gerontology, Nippon Medical School, Kawasaki, Japan. 3Awa Medical Association Hospital, Chiba, Japan. 4Department of Genome Research and Clinical Application, Graduate School of Medicine, Chiba University, Chiba, Japan. 5Department of Clinical Cell Biology, Graduate School of Medicine, Chiba University, Chiba, Japan. Aim: Not all genetic factors predisposing phenotypic features of dyslipidemia have been identified. We studied the association between the low density lipoprotein-related protein 2 gene (LRP2) and levels of plasma total cholesterol (T-Cho) and LDL-cholesterol (LDL-C) among 352 adults in Japan. Methods: Subjects were obtained from among participants in a cohort study that was carried out with health-check screening in an area of east-central Japan. We selected 352 individuals whose LDL-C levels were higher than 140 mg/dL from the initially screened 22,228 people. We assessed the relation between plasma cholesterol levels and single-nucleotide polymorphisms (SNPs) in the LRP2 gene. Results: -
Apoa5genetic Variants Are Markers for Classic Hyperlipoproteinemia
CLINICAL RESEARCH CLINICAL RESEARCH www.nature.com/clinicalpractice/cardio APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia 1 1 1 2 2 1 1 Jian Wang , Matthew R Ban , Brooke A Kennedy , Sonia Anand , Salim Yusuf , Murray W Huff , Rebecca L Pollex and Robert A Hegele1* SUMMARY INTRODUCTION Hypertriglyceridemia is a common biochemical Background Several known candidate gene variants are useful markers for diagnosing hyperlipoproteinemia. In an attempt to identify phenotype that is observed in up to 5% of adults. other useful variants, we evaluated the association of two common A plasma triglyceride concentration above APOA5 single-nucleotide polymorphisms across the range of classic 1.7 mmol/l is a defining component of the meta 1 hyperlipoproteinemia phenotypes. bolic syndrome and is associated with several comorbidities, including increased risk of cardio Methods We assessed plasma lipoprotein profiles and APOA5 S19W and vascular disease2 and pancreatitis.3,4 Factors, –1131T>C genotypes in 678 adults from a single tertiary referral lipid such as an imbalance between caloric intake and clinic and in 373 normolipidemic controls matched for age and sex, all of expenditure, excessive alcohol intake, diabetes, European ancestry. and use of certain medications, are associated Results We observed significant stepwise relationships between APOA5 with hypertriglyceridemia; however, genetic minor allele carrier frequencies and plasma triglyceride quartiles. The factors are also important.5,6 odds ratios for hyperlipoproteinemia types 2B, 3, 4 and 5 in APOA5 S19W Complex traits, such as plasma triglyceride carriers were 3.11 (95% CI 1.63−5.95), 4.76 (2.25−10.1), 2.89 (1.17−7.18) levels, usually do not follow Mendelian patterns of and 6.16 (3.66−10.3), respectively. -
Lrp1 Modulators
Last updated on February 14, 2021 Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Lrp1 Modulators Evidence Summary Lrp1 has a variety of essential functions, mediated by a diverse array of ligands. Therapeutics will need to target specific interactions. Neuroprotective Benefit: Lrp1-mediated interactions promote Aβ clearance, Aβ generation, tau propagation, brain glucose utilization, and brain lipid homeostasis. The therapeutic effect will depend on the interaction targeted. Aging and related health concerns: Lrp1 plays mixed roles in cardiovascular diseases and cancer, dependent on context. Lrp1 is dysregulated in metabolic disease, which may contribute to insulin resistance. Safety: Broad-spectrum Lrp1 modulators are untenable therapeutics due to the high potential for extensive side effects. Therapies that target a specific Lrp1-ligand interaction are expected to have a better therapeutic profile. 1 Last updated on February 14, 2021 Availability: Research use Dose: N/A Chemical formula: N/A S16 is in clinical trials MW: N/A Half life: N/A BBB: Angiopep is a peptide that facilitates BBB penetrance by interacting with Lrp1 Clinical trials: S16, an Lrp1 Observational studies: sLrp1 levels are agonist was tested in healthy altered in Alzheimer’s disease, volunteers (n=10) in a Phase 1 cardiovascular disease, and metabolic study. -
ABCA1 Gene ATP Binding Cassette Subfamily a Member 1
ABCA1 gene ATP binding cassette subfamily A member 1 Normal Function The ABCA1 gene belongs to a group of genes called the ATP-binding cassette family, which provides instructions for making proteins that transport molecules across cell membranes. The ABCA1 protein is produced in many tissues, with high amounts found in the liver and in immune system cells called macrophages. This protein moves cholesterol and certain fats called phospholipids across the cell membrane to the outside of the cell. These substances are then picked up by a protein called apolipoprotein A-I (apoA-I), which is produced from the APOA1 gene. ApoA-I, cholesterol, and phospholipids combine to make high-density lipoprotein (HDL), often referred to as "good cholesterol" because high levels of this substance reduce the chances of developing heart and blood vessel (cardiovascular) disease. HDL is a molecule that carries cholesterol and phospholipids through the bloodstream from the body's tissues to the liver. Once in the liver, cholesterol and phospholipids are redistributed to other tissues or removed from the body. The process of removing excess cholesterol from cells is extremely important for balancing cholesterol levels and maintaining cardiovascular health. Health Conditions Related to Genetic Changes Familial HDL deficiency Mutations in the ABCA1 gene can cause a condition called familial HDL deficiency. People with this condition have reduced levels of HDL in their blood and may experience early-onset cardiovascular disease, often before age 50. While one copy of the altered ABCA1 gene causes familial HDL deficiency, two copies of the altered gene cause a more severe related disorder called Tangier disease (described below). -
Common Genetic Variations Involved in the Inter-Individual Variability Of
nutrients Review Common Genetic Variations Involved in the Inter-Individual Variability of Circulating Cholesterol Concentrations in Response to Diets: A Narrative Review of Recent Evidence Mohammad M. H. Abdullah 1 , Itzel Vazquez-Vidal 2, David J. Baer 3, James D. House 4 , Peter J. H. Jones 5 and Charles Desmarchelier 6,* 1 Department of Food Science and Nutrition, Kuwait University, Kuwait City 10002, Kuwait; [email protected] 2 Richardson Centre for Functional Foods & Nutraceuticals, University of Manitoba, Winnipeg, MB R3T 6C5, Canada; [email protected] 3 United States Department of Agriculture, Agricultural Research Service, Beltsville, MD 20705, USA; [email protected] 4 Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada; [email protected] 5 Nutritional Fundamentals for Health, Vaudreuil-Dorion, QC J7V 5V5, Canada; [email protected] 6 Aix Marseille University, INRAE, INSERM, C2VN, 13005 Marseille, France * Correspondence: [email protected] Abstract: The number of nutrigenetic studies dedicated to the identification of single nucleotide Citation: Abdullah, M.M.H.; polymorphisms (SNPs) modulating blood lipid profiles in response to dietary interventions has Vazquez-Vidal, I.; Baer, D.J.; House, increased considerably over the last decade. However, the robustness of the evidence-based sci- J.D.; Jones, P.J.H.; Desmarchelier, C. ence supporting the area remains to be evaluated. The objective of this review was to present Common Genetic Variations Involved recent findings concerning the effects of interactions between SNPs in genes involved in cholesterol in the Inter-Individual Variability of metabolism and transport, and dietary intakes or interventions on circulating cholesterol concen- Circulating Cholesterol trations, which are causally involved in cardiovascular diseases and established biomarkers of Concentrations in Response to Diets: cardiovascular health. -
Apoe Lipidation As a Therapeutic Target in Alzheimer's Disease
International Journal of Molecular Sciences Review ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease Maria Fe Lanfranco, Christi Anne Ng and G. William Rebeck * Department of Neuroscience, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USA; [email protected] (M.F.L.); [email protected] (C.A.N.) * Correspondence: [email protected]; Tel.: +1-202-687-1534 Received: 6 August 2020; Accepted: 30 August 2020; Published: 1 September 2020 Abstract: Apolipoprotein E (APOE) is the major cholesterol carrier in the brain, affecting various normal cellular processes including neuronal growth, repair and remodeling of membranes, synaptogenesis, clearance and degradation of amyloid β (Aβ) and neuroinflammation. In humans, the APOE gene has three common allelic variants, termed E2, E3, and E4. APOE4 is considered the strongest genetic risk factor for Alzheimer’s disease (AD), whereas APOE2 is neuroprotective. To perform its normal functions, apoE must be secreted and properly lipidated, a process influenced by the structural differences associated with apoE isoforms. Here we highlight the importance of lipidated apoE as well as the APOE-lipidation targeted therapeutic approaches that have the potential to correct or prevent neurodegeneration. Many of these approaches have been validated using diverse cellular and animal models. Overall, there is great potential to improve the lipidated state of apoE with the goal of ameliorating APOE-associated central nervous system impairments. Keywords: apolipoprotein E; cholesterol; lipid homeostasis; neurodegeneration 1. Scope of This Review In this review, we will first consider the role of apolipoprotein E (apoE) in lipid homeostasis in the central nervous system (CNS). -
Additive Effects of LPL, APOA5 and APOE Variant Combinations On
Ariza et al. BMC Medical Genetics 2010, 11:66 http://www.biomedcentral.com/1471-2350/11/66 RESEARCH ARTICLE Open Access AdditiveResearch article effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study María-José Ariza*1, Miguel-Ángel Sánchez-Chaparro1,2,3, Francisco-Javier Barón4, Ana-María Hornos2, Eva Calvo- Bonacho2, José Rioja1, Pedro Valdivielso1,3, José-Antonio Gelpi2 and Pedro González-Santos1,3 Abstract Background: Hypertriglyceridemia (HTG) is a well-established independent risk factor for cardiovascular disease and the influence of several genetic variants in genes related with triglyceride (TG) metabolism has been described, including LPL, APOA5 and APOE. The combined analysis of these polymorphisms could produce clinically meaningful complementary information. Methods: A subgroup of the ICARIA study comprising 1825 Spanish subjects (80% men, mean age 36 years) was genotyped for the LPL-HindIII (rs320), S447X (rs328), D9N (rs1801177) and N291S (rs268) polymorphisms, the APOA5- S19W (rs3135506) and -1131T/C (rs662799) variants, and the APOE polymorphism (rs429358; rs7412) using PCR and restriction analysis and TaqMan assays. We used regression analyses to examine their combined effects on TG levels (with the log-transformed variable) and the association of variant combinations with TG levels and hypertriglyceridemia (TG ≥ 1.69 mmol/L), including the covariates: gender, age, waist circumference, blood glucose, blood pressure, smoking and alcohol consumption. Results: We found a significant lowering effect of the LPL-HindIII and S447X polymorphisms (p < 0.0001). In addition, the D9N, N291S, S19W and -1131T/C variants and the APOE-ε4 allele were significantly associated with an independent additive TG-raising effect (p < 0.05, p < 0.01, p < 0.001, p < 0.0001 and p < 0.001, respectively). -
Different Functional and Structural Characteristics Between Apoa-I and Apoa-4 in Lipid-Free and Reconstituted HDL State: Apoa-4 Showed Less Anti-Atherogenic Activity
Mol. Cells 2015; 38(6): 573-579 http://dx.doi.org/10.14348/molcells.2015.0052 Molecules and Cells http://molcells.org Established in 1990G Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity Jeong-Ah Yoo1,2,3,6, Eun-Young Lee1,2,3,6, Ji Yoon Park4, Seung-Taek Lee4, Sihyun Ham5, and Kyung-Hyun Cho1,2,3,* Apolipoprotein A-I and A-IV are protein constituents of INTRODUCTION high-density lipoproteins although their functional differ- ence in lipoprotein metabolism is still unclear. To compare High-density lipoprotein (HDL) is a complex mixture of lipids, anti-atherogenic properties between apoA-I and apoA-4, apolipoproteins, and enzymes in a phospholipid bilayer. we characterized both proteins in lipid-free and lipid- Apolipoprotein (apo) A-I, a 28-kDa single polypeptide, is a major bound state. In lipid-free state, apoA4 showed two distinct protein component of HDL (Frank and Marcel, 2000; Jonas, bands, around 78 and 67 Å on native gel electrophoresis, 1998). ApoA-I is responsible for the major functions of HDL, in- while apoA-I showed scattered band pattern less than 71 Å. cluding lipid binding and solubilization, cholesterol removal from In reconstituted HDL (rHDL) state, apoA-4 showed three peripheral cells, and activation of lecithin:cholesterol acyl- major bands around 101 Å and 113 Å, while apoA-I-rHDL transferase (LCAT) (Brouillette et al., 2001). ApoA4, a 46-kDa showed almost single band around 98 Å size. Lipid-free glycoprotein, is a minor apolipoprotein component of HDL and apoA-I showed 2.9-fold higher phospholipid binding ability chylomicron (Mahley et al., 1984), and it functions in LCAT than apoA-4. -
LRP1 Integrates Murine Macrophage Cholesterol Homeostasis And
RESEARCH ARTICLE LRP1 integrates murine macrophage cholesterol homeostasis and inflammatory responses in atherosclerosis Xunde Xian1†*, Yinyuan Ding1,2†, Marco Dieckmann1†, Li Zhou1, Florian Plattner3,4, Mingxia Liu5, John S Parks5, Robert E Hammer6, Philippe Boucher7, Shirling Tsai8,9, Joachim Herz1,4,10,11* 1Departments of Molecular Genetics, UT Southwestern Medical Center, Dallas, United States; 2Key Laboratory of Medical Electrophysiology, Ministry of Education of China, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, China; 3Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, United States; 4Center for Translational Neurodegeneration Research, University of Texas Southwestern Medical Center, Dallas, United States; 5Section on Molecular Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina; 6Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, United States; 7CNRS, UMR 7213, University of Strasbourg, Illkirch, France; 8Department of Surgery, UT Southwestern Medical Center, Dallas, United States; 9Dallas VA Medical Center, Dallas, United States; 10Department of Neuroscience, UT Southwestern, Dallas, United States; 11Department of Neurology and Neurotherapeutics, UT Southwestern, Dallas, United States *For correspondence: [email protected] (XX); [email protected] Abstract Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional cell (JH) surface -
Genetic Loci Associated with Changes in Lipid Levels Leading to Constitution
Chung et al. BMC Complementary and Alternative Medicine 2014, 14:230 http://www.biomedcentral.com/1472-6882/14/230 RESEARCH ARTICLE Open Access Genetic loci associated with changes in lipid levels leading to constitution-based discrepancy in Koreans Sun-Ku Chung1, Hyunjoo Yu1, Ah Yeon Park1, Jong Yeol Kim1,2 and Seongwon Cha1* Abstract Background: Abnormal lipid concentrations are risk factors for atherosclerosis and cardiovascular disease. The pathological susceptibility to cardiovascular disease risks such as metabolic syndrome, diabetes mellitus, hypertension, insulin resistance, and so on differs between Sasang constitutional types. Methods: We used multiple regression analyses to study the association between lipid-related traits and genetic variants from several genome-wide association studies according to Sasang constitutional types, considering that the Tae-Eum (TE) has predominant cardiovascular risk. Results: By analyzing 26 variants of 20 loci in two Korean populations (8,597 subjects), we found that 12 and 5 variants, respectively, were replicably associated with lipid levels and dyslipidemia risk. By analyzing TE and non-TE type (each 2,664 subjects) populations classified on the basis of Sasang constitutional medicine, we found that the minor allele effects of three variants enriched in TE type had a harmful influence on lipid risk (near apolipoprotein A-V (APOA5)-APOA4-APOC3-APOA1 on increased triglyceride: p=8.90 × 10−11,inAPOE-APOC1-APOC4 on increased low-density lipoprotein cholesterol: p=1.63 × 10−5, and near endothelial lipase gene on decreased high-density lipoprotein cholesterol: p=4.28 × 10−3), whereas those of three variants (near angiopoietin-like 3 gene, APOA5-APOA4-APOC3-APOA1, and near lipoprotein lipase gene on triglyceride and high-density lipoprotein cholesterol) associated in non-TE type had neutral influences because of a compensating effect. -
Apoa1 and Apoa1-Specific Self-Antibodies in Cardiovascular Disease Dimitry a Chistiakov1, Alexander N Orekhov2,3 and Yuri V Bobryshev2,4,5
Laboratory Investigation (2016) 96, 708–718 © 2016 USCAP, Inc All rights reserved 0023-6837/16 $32.00 PATHOBIOLOGY IN FOCUS ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease Dimitry A Chistiakov1, Alexander N Orekhov2,3 and Yuri V Bobryshev2,4,5 Apolipoprotein A1 (ApoA1) is a main protein moiety in high-density lipoprotein (HDL) particles. Generally, ApoA1 and HDL are considered as atheroprotective. In prooxidant and inflammatory microenvironment in the vicinity to the atherosclerotic lesion, ApoA1/HDL are subjected to modification. The chemical modifications such as oxidation, nitration, etc result in altering native architecture of ApoA1 toward dysfunctionality and abnormality. Neutrophil myeloperoxidase has a prominent role in this mechanism. Neo-epitopes could be formed and then exposed that makes them immunogenic. Indeed, these epitopes may be recognized by immune cells and induce production of proatherogenic ApoA1-specific IgG antibodies. These antibodies are biologically relevant because they are able to react with Toll-like receptor (TLR)-2 and TLR4 in target cells and induce a variety of pro-inflammatory responses. Epidemiological and functional studies underline a prognostic value of ApoA1 self-antibodies for several cardiovascular diseases, including myocardial infarction, acute coronary syndrome, and severe carotid stenosis. Laboratory Investigation (2016) 96, 708–718; doi:10.1038/labinvest.2016.56; published online 16 May 2016 Atherosclerosis-Associated Inflammation inflammation. These mediators also promote hyperplasia of At present, chronic inflammation is considered as a key VSMCs that begin to migrate and proliferate, and contribute pathophysiological mechanism in atherosclerosis.1 Inflamma- to the neointimal formation. Inflammatory mediators also tory reactions influence all studies of atherosclerotic progres- facilitate intraplaque neovascularization.